相关实验视频
Updated: Jul 23, 2025

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
Published on: October 4, 2022
在KRAS野生型胰腺癌中,瘤原始驱动因素和治疗脆弱性
Harshabad Singh1,2,3, Rachel B Keller1, Kevin S Kapner1
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
大约9%的胰腺癌缺乏KRAS突变. 这项研究确定了KRAS野生型 (WT) 胰腺管腺癌 (PDAC) 的替代驱动因素和治疗点,揭示了患者在发病时的年轻年龄.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 胰腺管腺癌 (PDAC) 是一种致命的癌症,大多数病例是由KRAS突变驱动的.
- 一个PDAC子集 (~8-10%) 缺乏KRAS突变,代表一个独特的分子实体.
- 了解KRAS野生型 (WT) PDAC对于开发向疗法和分层患者进行临床试验至关重要.
研究的目的:
- 为了描述KRAS WT胰腺癌的分子格局.
- 在这个PDAC子组中识别替代性瘤驱动因素和潜在的治疗点.
- 探索与KRAS WT PDAC相关的临床特征.
主要方法:
- 使用针对性多基因测序小组对795例外分胰腺癌病例的单一机构队列的分析.
- 鉴定了73名患有KRAS WT胰腺癌的患者 (9.2%).
- 使用患者衍生器官模型和临床数据分析的体外研究.
主要成果:
- 43.8%的KRAS WT病例具有其他MAPK路径驱动器 (BRAF突变,RTK融合).
- 29.3%的MAPK阴性KRAS WT病例显示其他致癌性改变 (GNAS,MYC,PIK3CA,CTNNB1).
- KRAS WT PDAC患者显著年轻;SMAD4突变与预后不佳相关.
结论:
- 这项研究定义了KRAS WT胰腺癌的基因组基础.
- 确定潜在的治疗策略,包括MAPK通路抑制和针对特定融合的向疗法.
- 突出了分子分析对KRAS WT PDAC治疗指导的重要性.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
07:08Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
相关概念视频
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Ras Gene
Ras is a...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...